RecruitingNCT06636383
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
GSDIa Disease Monitoring Program
Sponsor
Ultragenyx Pharmaceutical Inc
Enrollment
140 participants
Start Date
Nov 4, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration.
Eligibility
Min Age: 2 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying No Intervention for people with glycogen storage disease type ia. The study is currently recruiting participants at 19 locations. People eligible for this study include aged 2 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNo Intervention
No investigational/study product will be administered in this DMP.
Locations(19)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06636383
Related Trials
Accuracy of Home Lactate Meter and Accu-chek Glucometer in Patients With Glycogen Storage Disease
NCT074595821 location
Accuracy of Lactate Meter in GSDIa
NCT068433301 location
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
NCT067357553 locations